4//SEC Filing
Kalif Eliyahu Sharon 4
Accession 0000950170-25-035528
CIK 0000818686other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:19 PM ET
Size
9.6 KB
Accession
0000950170-25-035528
Insider Transaction Report
Form 4
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
Transactions
- Exercise/Conversion
Restricted Share Units
2025-03-05−21,390→ 0 total→ Ordinary Shares (21,390 underlying) - Exercise/Conversion
Ordinary Shares
2025-03-05+21,390→ 459,063 total - Award
Restricted Share Units
2025-03-05+79,664→ 79,664 total→ Ordinary Shares (79,664 underlying)
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022, March 5, 2023, March 5, 2024, and 21,390 vested on March 5, 2025.
- [F4]Restricted share units were granted on March 5, 2025, with 19,916 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001798443
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 4:19 PM ET
- Size
- 9.6 KB